NeuroSearch publishes promising meta-analysis of Huntexil studies
This article was originally published in Scrip
NeuroSearch, the Danish CNS-focused biotech, has published the results of a meta-analysis of pooled datasets from two previous trials – the Phase IIb HART and Phase III MermaiHD studies -- corroborating earlier conclusions that Huntexil (pridopidine), 45 mg twice daily, has potential to treat Huntington's disease. NeuroSearch intends to include the results of the meta-analysis in the clinical data package on Huntexil, which the company plans to present to and discuss with US and European regulators during the first half of 2011.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.